Latest Operating Expenses News

Singular Health boosted its US presence by deploying 500 additional 3DICOM MD® licenses to Provider Network Solutions, securing FDA 510(k) clearance for its cloud platform, and launching education pilots with Miami-Dade schools and Florida International University.

Metals Australia’s new PEA for its Quebec Battery Anode Material Refinery reveals robust economics with a $2.05 billion USD pre-tax NPV and a 25.6% IRR, underpinning plans for a final feasibility study.

Stonehorse Energy Limited reported steady operational and financial performance for Q1 2026, driven by successful drilling in Canada and solid oil and gas production across its North American portfolio.

Elevate Uranium Ltd pushes back its U-pgradeTM pilot plant results to August 2026 amid operational tweaks, while reporting a doubled resource grade at Marenica and a 76.2 Mlb uranium resource at Koppies.

Brazilian Rare Earths (ASX: BRE) has reported substantial expansion of its Monte Alto rare earth project with ultra high-grade drilling results and validated low-temperature processing delivering 97% recovery. The company also secured a Trial Mining Licence enabling early production and bulk shipments.

Gale Pacific reported a $1.3 million operating cash outflow in Q3 FY26 amid Middle East geopolitical tensions but strengthened its net cash position by $18 million year-on-year. The company is executing a revised strategy focused on expanding its US commercial footprint and diversifying manufacturing beyond China.

AdNeo (ASX:AD1) delivered its first positive operating cash flow quarter since its 2025 transformation, driven by strong revenue growth across all divisions and a growing $8m tender pipeline. The company advances its AI-first strategy while managing costs and acquisitions.

X2M Connect accelerated revenue growth in Q3 FY26 with a 67% increase, driven by strong demand in South Korea and new Australian smart community deals. The company’s capital raise and expanding customer base underpin its push into new markets despite ongoing cash burn.

Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.

Adisyn has confirmed a major graphene breakthrough compatible with semiconductor manufacturing and secured exclusive radar absorption rights, backed by a $14 million placement led by top institutional investors.

Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.

Stakk Ltd (ASX: SKK) has delivered a striking 272% jump in gross receipts to $5.36 million in Q3 FY26, reversing prior cash outflows with a positive net cash flow of $2.25 million and closing the quarter with $17.34 million in cash.